Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice

Gut

Volumn 62, Issue 7, 2013, Pages 1055-1061

  Shi, Niu ^a   Hiraga, Nobuhiko ^a   Imamura, Michio ^a   Hayes, C Nelson ^a   Zhang, Yizhou ^a   Kosaka, Keiichi ^a   Okazaki, Akihito ^a   Murakami, Eisuke ^a   Tsuge, Masataka ^a   Abe, Hiromi ^a   Aikata, Hiroshi ^a   Takahashi, Shoichi ^a   Ochi, Hidenori ^a,b   Tateno Mukaidani, Chise ^a,c   Yoshizato, Katsutoshi ^a,c   Matsui, Hirotaka ^a   Kanai, Akinori ^a   Inaba, Toshiya ^a   McPhee, Fiona ^d   Gao, Min ^d   Chayama, Kazuaki ^a,b   more..

^a HIROSHIMA UNIVERSITY   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^c PhoenixBio USA Corporation   (Japan)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BMS 605339; BMS 788329; BMS 821095; ENZYME INHIBITOR; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GENOTYPE; HEPATITIS C; HUMAN; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRUS RESISTANCE;

DRUG DEVELOPMENT; HCV;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; ISOQUINOLINES; MICE; MICE, SCID; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84878646257     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302600     Document Type: Article

References (32)

1. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5. (Pubitemid 20349249)
2. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95. (Pubitemid 28549142)
3. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005;280:36784-91. (Pubitemid 41587758)
4. Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 2005;49:4305-14. (Pubitemid 41400978)
5. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75.
6. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-8.
7. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int 2011;31(Suppl. 1):62-7.
8. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881-9; e881.
9. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-33. (Pubitemid 32756430)
10. Kneteman NM, Weiner AJ, O'Connell J, et al. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 2006;43:1346-53. (Pubitemid 43980114)
11. Hiraga N, Imamura M, Tsuge M, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett 2007;581:1983-7. (Pubitemid 46680431)
12. Ohara E, Hiraga N, Imamura M, et al. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol 2011;54:872-8.
13. Don RH, Cox PT, Wainwright BJ, et al. 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 1991;19:4008.
14. Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010;54:3641-50.
15. McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012;56:5387-96.
16. Sheaffer AK, Lee MS, Hernandez D, et al. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates. Antiviral Ther 2011;16:705-18.
17. Tateno C, Yoshizane Y, Saito N, et al. Near completely humanised liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165:901-12. (Pubitemid 39129297)
18. Kato T, Matsumura T, Heller T, et al. Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol 2007;81:4405-11. (Pubitemid 46668637)
19. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010;26:589-95.
20. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100.
21. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-62.
22. Kukolj G, McGibbon GA, McKercher G, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005;280:39260-7. (Pubitemid 41713879)
23. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38.
24. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
25. Paulson MS, Yang H, Shih IH, et al. Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus. Antiviral Res 2009;83:135-42.
26. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011;53:1090-9.
27. Imhof I, Simmonds P. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. J Virol 2010;84:4597-610.
28. Scheel TK, Gottwein JM, Mikkelsen LS, et al. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 2011;140:1032-42.
29. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005;41:832-5. (Pubitemid 40462946)
30. Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010;54:1878-87.
31. Cheng G, Chan K, Yang H, et al. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob Agents Chemother 2011;55:2197-205.
32. Delang L, Vliegen I, Froeyen M, et al. Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother 2011;55:4103-13.